141 results
Page 2 of 8
6-K
EX-99.1
tagn1m3 crc03w5rn
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
id57fyj
6 Jul 23
Current report (foreign)
6:18am
6-K
tzajx8y nxe1xlissf
28 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
yye77g qkkzedfa7yd
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
d1h i8vzv3h
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
urolh cwg2h
30 May 23
Current report (foreign)
6:11am
6-K
yb09d26wel6
17 May 23
Current report (foreign)
6:02am
6-K
hbolq9p mfb
11 May 23
Current report (foreign)
6:10am
6-K
47dwhen
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
7fm9dx e91r
11 May 23
Current report (foreign)
6:07am
6-K
0q450qukmv
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
s25l hhjg
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
xikug
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
lg3s4j
30 Nov 22
Current report (foreign)
6:28am
6-K
qlr3xio 04b
4 Nov 22
Current report (foreign)
6:01am
6-K
EX-99.1
4ghy80a jgdtdes
27 Oct 22
Current report (foreign)
6:01am
6-K
foje4
27 Oct 22
Current report (foreign)
6:01am
6-K
ipu pktwrr79p6cze1
14 Oct 22
Current report (foreign)
7:36am
6-K
6r1icgn c1yk593jr4
4 Oct 22
Current report (foreign)
6:06am